Table 1.
Simvastatin v placebo in high risk patients at mean 5 year follow up†
| Outcomes | Simvastatin | Placebo | RRR (95% CI | NNT (CI) |
|---|---|---|---|---|
| †Abbreviations defined in glossary; RRR, NNT, and CI calculated from data in article. | ||||
| ‡Nonfatal myocardial infarction or death from coronary disease. | ||||
| All cause mortality | 13% | 15% | 13% (6 to 19) | 58 (37 to 128) |
| Vascular mortality | 7.6% | 9.1% | 17% (9 to 25) | 66 (44 to 134) |
| Nonvascular mortality | 5.3% | 5.6% | 5% (−7 to 15) | Not significant |
| Major coronary event‡ | 8.7% | 12% | 27% (21 to 33) | 33 (26 to 46) |
| Stroke | 4.3% | 5.7% | 25% (15 to 34) | 73 (51 to 131) |
| Revascularisation | 9.1% | 12% | 24% (17 to 30) | 39 (29 to 58) |
